| Literature DB >> 28458712 |
Lixia Yang1, Zhicheng Wang2, Liangen Jiang3, Wen Sun4, Qiang Fan3, Tonghua Liu4.
Abstract
Background. Insulin resistance (IR) is the main etiology of type 2 diabetes mellitus (T2DM). It has been known that total flavonoid extracts can markedly improve the hypoglycemic symptoms caused by IR. Nevertheless, the relevant molecular mechanism remains unclarified. Aim. This study aimed to investigate the antihyperglycemic effects and mechanism of the total flavonoid extract from Oxytropis falcata Bunge. Methods. STZ-induced T2DM rats (n = 35) were divided into 5 groups: model, low-, medium-, and high-dose total flavonoids, and pioglitazone groups. Ten healthy rats were used as controls. The serum insulin and inflammatory cytokines (MCP-1, TNF-α, and IL-6) level was measured by ELISA. The concentration of IRS-1, p-IRS-1, PKB p-PKB, PI3Kp85, and p-PI3K in skeletal muscles was determined by Western blot. The mRNA level of GLUT4, IκB, and NF-κB in skeletal muscle was detected by qRT-PCR. Results. The treatment of medium- and high-dose total flavonoids significantly reduced the FPG and P2hPG and enhanced insulin level in T2DM rats (P < 0.05). When compared with controls, the serum level of MCP-1, TNF-α, IL-6, IRS-1, and p-IRS-1 was significantly increased in T2DM rats, but the level of PKB, p-PKB, PI3Kp85, and p-PI3K expression was reduced (P < 0.05). The GLUT4 and IκB mRNA expression were significantly decreased, and NF-κB mRNA level was increased (P < 0.05). The treatment of low-, medium-, or high-dose total flavonoids markedly reversed the changes above (P < 0.05). Conclusion. Our study has confirmed the therapeutic effects of total flavonoids from Oxytropis falcata Bunge on IR. The flavonoids might reduce the production of inflammatory cytokines through downregulation of NF-κB expression in inflammatory pathway and regulate the IRS-1-PI3-K-PKB/Akt insulin pathway and thereby increased the GLUT4 expression.Entities:
Year: 2017 PMID: 28458712 PMCID: PMC5385212 DOI: 10.1155/2017/2405124
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Comparison of serum level of FPG, P2hPG, and insulin in difference groups (n = 7, ).
| Group | Dosage (mg·kg−1) | FPG (mmol/l) | P2hPG (mmol/l) | Insulin (nIU/ml) |
|---|---|---|---|---|
| Normal control | — | 4.30 ± 0.20 | 6.06 ± 0.44 | 90.04 ± 18.73 |
| Model | — | 25.34 ± 3.88(1) | 28.90 ± 3.38(1) | 19.42 ± 19.36(1) |
| Pioglitazone | 10 | 11.80 ± 1.04(2) | 14.74 ± 2.26(2) | 43.44 ± 57.10(2) |
| Low-dose total flavonoids | 100 | 22.86 ± 4.64 | 25.69 ± 4.34 | 36.52 ± 33.85 |
| Medium-dose total flavonoids | 200 | 16.09 ± 2.25(2) | 19.89 ± 1.91(2) | 47.40 ± 34.77(2) |
| High-dose total flavonoids | 400 | 13.13 ± 0.80(2) | 14.34 ± 2.12(2) | 49.60 ± 47.60(2) |
(1) P < 0.05 compared with normal control group and (2)P < 0.05 compared with model group.
Comparison of serum level of MCP-1, TNF-α, and IL-6 in different groups (n = 7, ).
| Group | Dosage (mg·kg−1) | MCP-1 (pg/ml) | TNF- | IL-6 (pg/ml) |
|---|---|---|---|---|
| Normal control | — | 88.83 ± 23.69 | 104.44 ± 10.84 | 65.44 ± 5.61 |
| Model | — | 172.03 ± 78.84(1) | 131.92 ± 44.13(1) | 120.30 ± 102.16(1) |
| Pioglitazone | 10 | 111.34 ± 26.25(2) | 109.29 ± 14.90(2) | 83.58 ± 44.60(2) |
| Low-dose total flavonoids | 100 | 156.19 ± 92.01 | 120.53 ± 27.42 | 92.93 ± 25.60(2) |
| Medium-dose total flavonoids | 200 | 101.84 ± 31.71(2) | 116.62 ± 15.56 | 68.84 ± 20.76(2) |
| High-dose total flavonoids | 400 | 133.54 ± 51.55 | 114.67 ± 21.28 | 48.68 ± 32.57(2) |
(1) P < 0.05 compared with normal control group and (2)P < 0.05 compared with model group.
Comparison of the expression of insulin signaling molecules in skeletal muscles in different groups (n = 3, ).
| Group | Dosage (mg·kg−1) | IRS-1 | p-IRS-1 | PKB | p-PKB | PI3Kp85 | p- PI3K |
|---|---|---|---|---|---|---|---|
| Normal control | — | 0.12 ± 0.06 | 0.22 ± 0.08 | 1.90 ± 0.80 | 1.52 ± 0.39 | 1.56 ± 0.79 | 1.38 ± 0.24 |
| Model | — | 0.99 ± 0.44(1) | 0.75 ± 0.09(1) | 0.76 ± 0.33(1) | 0.40 ± 0.04(1) | 0.59 ± 0.34(1) | 0.52 ± 0.11(1) |
| Pioglitazone | 10 | 0.87 ± 0.36 | 0.43 ± 0.28(2) | 1.36 ± 0.50(2) | 0.93 ± 0.24(2) | 0.90 ± 0.55(2) | 1.01 ± 0.10(2) |
| Low-dose total flavonoids | 100 | 0.36 ± 0.12(2) | 0.55 ± 0.35 | 1.01 ± 0.48(2) | 1.01 ± 0.40(2) | 0.78 ± 0.41 | 1.50 ± 0.16(2) |
| Medium-dose total flavonoids | 200 | 0.36 ± 0.10(2) | 0.56 ± 0.18 | 1.66 ± 0.57(2) | 1.14 ± 0.50(2) | 0.93 ± 0.23(2) | 1.10 ± 0.38(2) |
| High-dose total flavonoids | 400 | 0.44 ± 0.32(2) | 0.42 ± 0.21(2) | 0.82 ± 0.11 | 1.42 ± 0.09(2) | 1.07 ± 0.24(2) | 0.88 ± 0.21 |
(1) P < 0.05 compared with normal control group and (2)P < 0.05 compared with model group.
Figure 1Western blot analysis of the expression of insulin signaling molecules in skeletal muscles in different groups (a) IRS-1 and p-IRS-1; (b) PKB and p-PKB; and (c) PI3Kp85 and p-PI3Kp85. (1) Normal control, (2) model group, (3) pioglitazone, (4) low-dose total flavonoids, (5) medium-dose total flavonoids, and (6) high-dose total flavonoids.
Comparison of the mRNA expression of GLUT4, IκB, and NF-κB in skeletal muscles in different groups (n = 3, ).
| Group | Dosage (mg·kg−1) | GLUT4 | I | NF- |
|---|---|---|---|---|
| Normal control | — | 1.351 ± 1.18 | 1.003 ± 0.09 | 1.253 ± 0.79 |
| Model | — | 0.098 ± 0.04(1) | 0.539 ± 0.11(1) | 8.881 ± 4.46(1) |
| Pioglitazone | 10 | 0.674 ± 0.14(2) | 0.842 ± 0.78 | 3.609 ± 1.69(2) |
| Low-dose total flavonoids | 100 | 0.182 ± 0.06(2) | 0.526 ± 0.33 | 3.968 ± 1.45(2) |
| Medium-dose total flavonoids | 200 | 0.355 ± 0.05(2) | 0.848 ± 0.57 | 3.621 ± 0.65(2) |
| High-dose total flavonoids | 400 | 0.234 ± 0.08(2) | 0.867 ± 0.62 | 2.695 ± 0.70(2) |
(1) P < 0.05 compared with normal control group and (2)P < 0.05 compared with model group.